D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
Pulse Biosciences, Inc. (NASDAQ:PLSE) announced Monday the appointment of Steven T. Weber as Vice President of Accounting and Global Corporate Controller, effective immediately. In this role, Mr. Weber will also serve as the company’s principal accounting officer.
According to a press release statement, Mr. Weber brings over 25 years of finance experience. He most recently served as Senior Vice President, Corporate Controller, and Principal Accounting Officer at IGM Biosciences (NASDAQ:IGMS) from March 2022 to July 2025. Prior to that, he held several positions at Aeglea Biotherapeutics (NASDAQ:SYRE), including Vice President and Principal Accounting Officer. Mr. Weber began his career at PricewaterhouseCoopers LLP and is a certified public accountant in Texas. He holds a B.B.A. in Accounting and an M.P.A. from the University of Texas at Austin.
Pulse Biosciences stated that Mr. Weber’s employment is at-will and compensation is consistent with the company’s practices for vice presidents. He is eligible to participate in standard employee benefit plans.
As part of his appointment, Mr. Weber received a stock option to purchase up to 55,000 shares of Pulse Biosciences common stock at an exercise price of $16.03 per share, the closing price on July 11, 2025. Half of these options will vest over four years, with 25% vesting on the first anniversary of his start date and the remainder vesting annually over the following three years. The other half will vest in four equal parts based on the company reaching market capitalization milestones of $1.5 billion, $2.25 billion, $3.0 billion, and $4.0 billion for 270 consecutive days or on specified future dates. For deeper insights into PLSE’s valuation metrics and growth potential, InvestingPro subscribers can access comprehensive analysis, including 8 additional ProTips and detailed financial metrics.
The company reported there are no family relationships or related party transactions involving Mr. Weber, and his selection was not made pursuant to any arrangement with another person.
This information is based on a press release statement included in a filing with the Securities and Exchange Commission. Looking ahead, analysts have set a price target of $22 for PLSE, and the company is scheduled to report its next earnings on August 6, 2025. A detailed analysis of the company’s financial health and growth prospects is available in the Pro Research Report on InvestingPro, part of their coverage of over 1,400 US stocks.
In other recent news, Pulse Biosciences reported a net loss of $16.8 million for the first quarter of 2025, highlighting increased expenses as the company invests in the development of its nanosecond pulse field ablation (NSPFA) technology. Despite the loss, Pulse Biosciences raised $14 million through warrant exercises, maintaining a strong cash position of $119.3 million. The company plans to generate revenue in the latter half of 2025 as it continues to advance its NSPFA technology and expand its clinical trials. Oppenheimer has initiated coverage on Pulse Biosciences with an Outperform rating, citing the potential of the company’s NSPFA technology and expressing confidence in its leadership. The firm noted that while pivotal trials are necessary to validate the technology’s benefits, the science behind Pulse Biosciences’ approach is promising. The company is also expanding its clinical sites in Europe for catheter studies and aims to establish best practices for site care by the second quarter. Pulse Biosciences anticipates that its NSPFA technology could significantly advance treatments for atrial fibrillation and other conditions, with plans to start IDE pivotal clinical trials mid-year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.